The severity of carotid arteriosclerosis was evaluated by two-dimensional carotid echography, and the relationship with coronary artery disease and asymptomatic cerebral infarction was studied. Carotid arteriosclerosis was classified into four types (Category I to IV) by the method of J. T. Salonen et al. The thickness of the carotid intima and media tended to increase with age in healthy individuals, but it almost never exceeded 1 mm even in the elderly. When the incidende of carotid artery lesions and asymptomatic cerebrel infarction were investigated in 156 subjects, they were present in one out of four Category I subjects, six out of 37 Category II subjects, 49 out of 81 Category III subjects, and 19 out of 27 Category IV. A high incidence of asymptomatic cerebrel infarction was seen in subjects who were Category III or higher. Coronary artery disease was compared with carotid artery lesions in 118 subjects undergoing coronary angiography. An increase in the severity of carotid arteriosclerosis was associated with an increase in the presence of significant coronary artery stenosis and also with an increase in multivessel coronary disease. There was no difference in the prevalence of carotid arteriosclerosis between subjects with effort angina or myocardial infarction who had only singlevessel disease, but among subjects with multivessel disease those who had effort angina showed more advanced carotid lesions than those with myocardial infarction. These results indicated a relationship between the severity of carotid arteriosclerosis determined using twodimensional echography and the presence of cerebral infarction and coronary artery disease, suggesting that it is possible to predict the existence of these disease to some extent.
I'd like to speak from the standpoint of view in both recently applicable diagnosis of coagulofibrinosis, hepatic fibrosis and hepatitis-related virus markers and the therapy of abnormal coagulofibrinolysis, plasma aminoacids, also as of Interferon. The coagulofibrinolysis-related tests ought to be more highly appreciated from the pathophysiological standpoint of diagnosis, prediction of severity and prognosis of liver diseases (eg. DIC). Such as thrombomodulin, thrombin-antithrombin complex (TAT), tissue-plasminogen activator (t-PA), plasmin-plasmin inhivitor (PIP) are included. As to the therapy, methyl gabexate (FOY®) which has both pharmatheutical effects of antithrombin and anti-plasmin is better to be used to prevent the development to severe liver damage from the earlier stage. Prolyl hydroxylase, procollagen typeIII peptide (PIIIP), typeIV collagen are excellent parametersto reflect directly the hepatic fibrogenesis and fibrosis, instead of ZTT, γ-globulin In cases of severe liver diseases, aromatic aminoacid (AAA) is decresed, on the other hand branched amino acid (BCAA) is increased, resulting to decrease in BCAA/AAA ratio. BCAA is synthesized to glutamine in the muscle and metabolized to alanine and ammonia. BCAA administration improves the plasma aminoacid unbalance, albumin, Ch-E, total cholesterol and levels conciousness disturbance in chronic severe liver diseases. The effects of Interferon on chronic B, C-hepatitis are influenced with the factors of virus copies, genotype, variation (hypervariable region) from virus side, and from host side, hepatic tissue stage, age, immunological responce. On the administration, above mentioned factors shoud be taken into a consideration comprehensively.